Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes

Table 2 Number (%) of Korean patients with adverse events, SAEs, and discontinuations (safety population)

	Vilda/Pio 100/30 mg q.d. (N = 34) n (%)	Vilda/Pio 50/15 mg q.d. (N = 34) n (%)	Vilda 100 mg q.d. (N = 35) n (%)	Pio 30 mg q.d. (N = 36) n (%)
Any primary system organ class AE	13 (38.2)	15 (44.1)	13 (37.1)	13 (36.1)
Common AEs
Nasopharyngitis	0	4 (11.8)	2 (5.7)	3 (8.3)
Dizziness	2 (5.9)	1 (2.9)	2 (5.7)	3 (8.3)
Headache	3 (8.8)	1 (2.9)	0	0
Upper respiratory tract infection	0	0	2 (5.7)	2 (5.6)
Asthenia	1 (2.9)	1 (2.9)	0	2 (5.6)
Constipation	0	0	2 (5.7)	1 (2.8)
AEs leading to discontinuations	2 (5.9)	2 (5.9)	1 (2.9)	1 (2.8)
Headache	1 (2.9)	0	0	0
Hepatitis	1 (2.9)	0	0	0
Cerebral hemorrhage	0	1 (2.9)	0	0
Colon cancer	0	1 (2.9)	1 (2.9)	0
Generalized edema	0	0	0	1 (2.8)
SAEs	1 (2.9)	2 (5.9)	1 (2.9)	0
Thermal burn	1 (2.9)	0	0	0
Cerebral hemorrhage	0	1 (2.9)	0	0
Colon cancer	0	1 (2.9)	1 (2.9)	0

AEs: adverse events.